NCT06690671View on ClinicalTrials.gov

A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

Golidocitinib in combination with anti-PD-1

Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.

Trial Locations (1)

200030

241, West Huaihai Road, Shanghai, Shanghai, Shanghai 200030, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER